Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORT1 | Q99523 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13011343 | 0.78 | — | — | |
| SCHEMBL13750027 | 0.76 | — | — | |
| SCHEMBL18117237 | 0.73 | — | — | |
| SCHEMBL19983207 | 0.72 | — | — | |
| SCHEMBL19622228 | 0.71 | — | — | |
| SCHEMBL16230233 | 0.71 | — | — | |
| SCHEMBL23970060 | 0.68 | — | — | |
| SCHEMBL23075960 | 0.67 | — | — | |
| SCHEMBL19930572 | 0.67 | SORT1 (0.39) | SORT1 | |
| SCHEMBL22268516 | 0.66 | ALDH1A1 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053202-B2 | Compositions for the treatment of hypertension and/or fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2021-07-06 | — | — | US | disclosed |
| US-20200255384-A9 | Compositions for the Treatment of Hypertension and/or Fibrosis | VECTUS BIOSYSTEMS LIMITED (AU) | 2020-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200255384-A9 | Compositions for the Treatment of Hypertension and/or Fibrosis | TGFB1, REN, TGFB2 | SORT1 1970/4885 |
| US-11053202-B2 | Compositions for the treatment of hypertension and/or fibrosis | TGFB1, REN, TGFB2 | SORT1 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.